Andera Partners Reinvests in Tubulis’ €308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

EQS-News: Andera Partners / Key word(s): Financing Andera Partners Reinvests in Tubulis’ €308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline 15.10.2025 / 11:10 CET/CEST The issuer is solely responsible for the content of this announcement. Andera Partners Reinvests in Tubulis’ €308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

• Andera Partners, which led the €60 million Series B financing in 2022, invests in the Series C round alongside lead investor Venrock Healthcare Capital Partners and other new investors Wellington Management and Ascenta Capital, as well as existing investors
• USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally

Paris, France – October 15^th, 2025 – Andera Partners, a leading European private equity player, today announced that it participated in the €308 million (USD 361 million) Series C financing of its portfolio company Tubulis, underscoring Andera’s continued support of the company’s growth and clinical development progress. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C in addition to Andera Partners include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT, and Seventure Partners.

The proceeds from the Series C financing will be used to expand the clinical development of TUB-040, Tubulis’ lead antibody-drug conjugate (ADC) candidate, into earlier lines of therapy and additional tumor indications. TUB-040 targets NaPi2b, an antigen that is overexpressed in ovarian cancer and lung adenocarcinomas. TUB-040 is currently being evaluated in a Phase I/IIa study (NAPISTAR1-01, NCT06303505) in patients with platinum-resistant ovarian cancer (PROC) as well as relapsed or refractory non-small cell lung cancer and was granted Fast Track designation by the U.S. FDA in June 2024. The capital will also advance Tubulis’ pipeline, including the clinical-stage ADC candidate TUB-030, several preclinical programs, and expand its proprietary ADC platform technologies to bring ADCs into novel applications.